Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
A medical oncologist, pharmacist, nurse, and patient review current immunotherapy options across the kidney and bladder cancer treatment landscape and discuss the unmet needs that remain for patients on long-term therapy.
A medical oncologist, pharmacist, nurse, and patient review current immunotherapy options across the kidney and bladder cancer treatment landscape and discuss the unmet needs that remain for patients on long-term therapy.
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
The panel reviews the clinical data behind subcutaneous pembrolizumab and nivolumab, comparing efficacy and pharmacokinetics to their IV counterparts, and shares early clinical impressions of introducing these formulations into practice.
The panel reviews the clinical data behind subcutaneous pembrolizumab and nivolumab, comparing efficacy and pharmacokinetics to their IV counterparts, and shares early clinical impressions of introducing these formulations into practice.
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
Experts and a patient discuss the practical advantages of subcutaneous immunotherapy for genitourinary cancers, including reduced chair time, less discomfort, and the resulting impact on patient quality of life and treatment burden.
Experts and a patient discuss the practical advantages of subcutaneous immunotherapy for genitourinary cancers, including reduced chair time, less discomfort, and the resulting impact on patient quality of life and treatment burden.
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
This article reviews the current standard and subcutaneous immunotherapy options for renal cell carcinoma and bladder cancer, and outlines the patient-facing benefits and practical steps for integrating subcutaneous administration into...
This article reviews the current standard and subcutaneous immunotherapy options for renal cell carcinoma and bladder cancer, and outlines the patient-facing benefits and practical steps for integrating subcutaneous administration into...